Clinical Research Papers:
Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma
Metrics: PDF 850 views | HTML 1180 views | ?
Pier Francesco Ferrucci1, Sara Gandini2, Emilia Cocorocchio1, Laura Pala1, Federica Baldini3, Massimo Mosconi3, Gian Carlo Antonini Cappellini4, Elena Albertazzi2 and Chiara Martinoli1
1Medical Oncology of Melanoma Unit, Division of Medical Oncology of Melanoma and Sarcoma, European Institute of Oncology, Milan, Italy
2Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
3Division of Surgery of Melanoma and Sarcoma, European Institute of Oncology, Milan, Italy
4IV Oncology Division, Istituto Dermopatico dell’Immacolata IRCCS, Rome, Italy
Pier Francesco Ferrucci, email: firstname.lastname@example.org
Keywords: eosinophil, predictive, biomarker, ipilimumab, melanoma
Received: May 17, 2017 Accepted: June 30, 2017 Published: August 01, 2017
As diverse therapeutic options are now available for advanced melanoma patients, predictive markers that may assist treatment decision are needed. A model based on baseline serum lactate dehydrogenase (LDH), peripheral blood relative lymphocyte counts (RLC) and eosinophil counts (REC) and pattern of distant metastasis, has been recently proposed for pembrolizumab-treated patients. Here, we applied this model to advanced melanoma patients receiving chemotherapy (n = 116) or anti-CTLA-4 therapy (n = 128). Visceral involvement, LDH and RLC were associated with prognosis regardless of treatment. Instead, when compared to chemotherapy-treated patients with REC < 1.5%, those with REC ≥ 1.5% had improved overall survival when receiving anti-CTLA-4 [Hazard Ratio (HR) = 0.56 (0.4–0.93)] but not chemotherapy [HR = 1.13, (0.74–1.74)], and the treatment-by-REC interaction was significant for both overall (p = 0.04) and progression free survival (p = 0.009). These results indicate baseline REC ≥ 1.5% as a candidate predictive biomarker for benefit from anti-CTLA-4. Further studies are needed to confirm these findings in patients receiving immune-modulating agents.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.